201
Participants
Start Date
January 25, 2017
Primary Completion Date
June 21, 2022
Study Completion Date
June 21, 2022
BGB-3111
160 mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
Ibrutinib
420 mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
Fondazione Policlinico A Gemelli, Roma
Royal North Shore Hospital, St Leonards
St George Hospital, Kogarah
Paratus Clinical Research Woden, Canberra
Peter Maccallum Cancer Centre, Melbourne
St Vincents Hospital Melbourne, Fitzroy
Monash Health, Clayton
Peninsula Health Frankston, Frankston
Barwon Health the Geelong Hospital, Geelong
Princess Alexandra Hospital, Brisbane
Flinders Medical Centre, Bedford PK
Sir Charles Gairdner Hospital, Nedlands
Hospital Clinic de Barcelona, Barcelona
Vseobecna Fakultni Nemocnice V Praze, Prague
Ao Citta Della Salute E Della Scienza Di Torino Presidio O, Torino
General Hospital of Athens Alexandra, Athens
Niguarda Cancer Center Division of Hematology, Milan
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Brescia
Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi, Pavia
Start Madrid Fundacion Jimenez Diaz, Madrid
Aou Maggiore Della Carita, Novara
Aou Santa Maria Della Misericordia Di Udine, Udine
Hospital Universitario de Salamanca, Salamanca
Sarah Cannon Cancer Center, Nashville
Policlinico Sorsola Malpighi, Aou Di Bologna, Bologna
Hospital Universitari I Politecnic La Fe, Valencia
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst, Meldola
Unita Di Ematologia, Dipartimento Di Ematologia Ed Oncologia, Ravenna
Fakultni Nemocnice Hradec Kralove, Hradec Králové
Mayo Clinic Rochester, Rochester
Centre Leon Berard, Lyon
Srh Kliniken Landkreis Sigmaringen, Sigmaringen
Colorado Blood Cancer Institute, Denver
Mayo Clinic Phoenix, Phoenix
Universitaetsklinikum Ulm, Innere Medizin Iii, Ulm
City of Hope National Medical Center, Duarte
Seattle Cancer Care Alliance, Seattle
Dana Farber Cancer Institute, Boston
Fakultni Nemocnice Ostrava, Ostrava
Amsterdam Umc Amc, Amsterdam
Universitair Medisch Centrum Utrecht, Utrecht
Uniwersytecki Szpital Kliniczny W Bialymstoku, Bialystok
Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny, Brzozów
Szpital Uniwersytecki Nr Im Dr Jana Biziela, Bydgoszcz
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Chorzów
Malopolskie Centrum Medyczne Sc, Krakow
Hospital Universitari Germans Trias I Pujol, Badalona
Hospital de La Santa Creu I Sant Pau, Barcelona
Hospital Universitario Vall Dhebron, Barcelona
Ico H Duran I Reynals, Barcelona
Karolinska Universitetssjukhuset Solna, Stockholm
The Royal Bournemouth and Christchurch Hospitals Nhs Foundation, Bournemouth
Churchill Hospital Oxford University Hospital Nhs Trust, Headington
St Jamess Institute of Oncology, Leeds
Barts Health Nhs Trust, London
University College Hospital, London
Nottingham University Hospitals Nhs Trust, Nottingham
Plymouth Hospitals Nhs Trust, Plymouth
Lead Sponsor
BeiGene
INDUSTRY